Analysts’ updated eps estimates for Wednesday, September 6th:
Barratt Developments Plc (LON:BDEV) had its hold rating reiterated by analysts at Peel Hunt. They currently have a GBX 635 ($8.20) price target on the stock.
Bellerophon Therapeutics (NASDAQ:BLPH) had its buy rating reiterated by analysts at HC Wainwright.
Faron Pharmaceuticals Oy (LON:FARN) had its buy rating reaffirmed by analysts at Panmure Gordon.
Hewlett Packard Enterprise (NYSE:HPE) had its buy rating reiterated by analysts at UBS AG. UBS AG currently has a $16.00 price target on the stock, down from their previous price target of $21.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.
Insmed (NASDAQ:INSM) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $35.00 target price on the stock.
Mastercard (NYSE:MA) had its positive rating reiterated by analysts at Wedbush. They currently have a $140.00 price target on the stock, up from their previous price target of $129.00.
MorphoSys AG (ETR:MOR) had its neutral rating reiterated by analysts at J P Morgan Chase & Co.
Merck KGaA (FRA:MRK) had its neutral rating reaffirmed by analysts at J P Morgan Chase & Co.
Synairgen plc (LON:SNG) had its under review rating reissued by analysts at N+1 Singer.
Xaar plc (LON:XAR) had its buy rating reissued by analysts at Peel Hunt. They currently have a GBX 470 ($6.07) price target on the stock.
